Houston based GB Sciences, Inc. (OTCQB:GBLX) a cannabis company focused on standardized cultivation and production methods as well as biopharmaceutical research and development, announced it has developed plants with a THC-a content of 35.119%, a very high concentration.
The stock was up 7% today to $0.60, and has nearly tripled in the past month. The company’s goal is creating standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions.
The company announced the strain also has a specifically-defined terpene profile, meaning it may also have significant medical benefits. The plant produced β-myrcene levels of 2.18% and β-caryophyllene levels of 1.01%, as tested by independent lab Digipath Labs, Inc. in Las Vegas.
On December 5, 2017 the company announced that 100% of the mother plants in their Las Vegas cultivation facility are products of their tissue propagation initiative. Commercial tissue propagation is thought to be an ‘urban myth’ by many in the industry. The company is enjoying consistently high crop yields and sharp monthly revenue increases over the past two months.
A mother plant is a plant in its vegetative state that does not produce flowers, only branches and leaves,
Dr. Reimann-Philipp of GB Sciences said “Tissue culture propagation is the next wave in the production of pure medical grade cannabis at commercial scale. GB Sciences is proud to be at the forefront of this movement. R&D in all facets of the cannabis industry is in our corporate DNA, and we use every means possible to explore and innovate the absolute best methods for turning Cannabis into medicine.”
GBLX’s growth strategy is two-pronged: it sells recreational cannabis in Nevada, and uses the profits to to explore biomedical research for the development of cannabis-based therapies